Concepts (202)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Vitiligo | 15 | 2023 | 120 | 3.420 |
Why?
|
| Skin | 12 | 2026 | 422 | 2.720 |
Why?
|
| Lupus Erythematosus, Cutaneous | 3 | 2026 | 16 | 2.280 |
Why?
|
| Skin Diseases | 4 | 2024 | 80 | 1.780 |
Why?
|
| Dermatitis | 3 | 2024 | 27 | 1.690 |
Why?
|
| CD8-Positive T-Lymphocytes | 10 | 2023 | 676 | 1.460 |
Why?
|
| Chemokine CXCL10 | 10 | 2023 | 56 | 1.340 |
Why?
|
| Interleukin-16 | 5 | 2014 | 25 | 1.280 |
Why?
|
| T-Lymphocytes | 4 | 2026 | 1008 | 1.200 |
Why?
|
| Autoimmune Diseases | 3 | 2026 | 239 | 1.150 |
Why?
|
| Receptors, CXCR3 | 7 | 2023 | 35 | 1.140 |
Why?
|
| Scleroderma, Localized | 3 | 2023 | 11 | 1.090 |
Why?
|
| Dog Diseases | 3 | 2026 | 47 | 1.090 |
Why?
|
| Chemokines | 2 | 2019 | 92 | 1.050 |
Why?
|
| Dysbiosis | 2 | 2026 | 74 | 0.930 |
Why?
|
| Antigen-Presenting Cells | 1 | 2026 | 178 | 0.890 |
Why?
|
| Immunologic Memory | 4 | 2021 | 284 | 0.890 |
Why?
|
| Melanocytes | 4 | 2023 | 77 | 0.880 |
Why?
|
| Gastrointestinal Microbiome | 2 | 2026 | 263 | 0.860 |
Why?
|
| S100 Proteins | 1 | 2024 | 20 | 0.860 |
Why?
|
| Signal Transduction | 7 | 2022 | 3153 | 0.830 |
Why?
|
| Homeostasis | 2 | 2024 | 379 | 0.780 |
Why?
|
| Animals | 27 | 2026 | 21345 | 0.720 |
Why?
|
| Janus Kinase Inhibitors | 4 | 2023 | 20 | 0.690 |
Why?
|
| Immunotherapy | 3 | 2023 | 274 | 0.670 |
Why?
|
| Uveomeningoencephalitic Syndrome | 1 | 2020 | 4 | 0.670 |
Why?
|
| Pigmentation Disorders | 1 | 2020 | 9 | 0.660 |
Why?
|
| Epidermis | 2 | 2018 | 35 | 0.630 |
Why?
|
| Immunologic Factors | 1 | 2021 | 110 | 0.630 |
Why?
|
| Mice | 19 | 2026 | 11119 | 0.630 |
Why?
|
| Th1 Cells | 3 | 2022 | 171 | 0.620 |
Why?
|
| Lipopolysaccharides | 2 | 2012 | 625 | 0.600 |
Why?
|
| CD4-Positive T-Lymphocytes | 3 | 2021 | 641 | 0.600 |
Why?
|
| Disease Models, Animal | 8 | 2026 | 2293 | 0.570 |
Why?
|
| Antibodies, Blocking | 1 | 2018 | 39 | 0.560 |
Why?
|
| Interleukin-15 | 1 | 2018 | 25 | 0.560 |
Why?
|
| Mycobacterium tuberculosis | 2 | 2012 | 422 | 0.540 |
Why?
|
| Chemokine CXCL9 | 6 | 2023 | 23 | 0.530 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2019 | 241 | 0.530 |
Why?
|
| Transcriptome | 3 | 2026 | 399 | 0.520 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2019 | 221 | 0.500 |
Why?
|
| Fibrosis | 3 | 2023 | 172 | 0.490 |
Why?
|
| Antibodies | 1 | 2017 | 187 | 0.480 |
Why?
|
| Mannose | 2 | 2012 | 22 | 0.470 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2026 | 583 | 0.450 |
Why?
|
| Inflammation | 4 | 2026 | 1192 | 0.440 |
Why?
|
| Antigens, Bacterial | 2 | 2012 | 202 | 0.430 |
Why?
|
| Humans | 30 | 2026 | 65140 | 0.430 |
Why?
|
| Protein Precursors | 2 | 2011 | 85 | 0.420 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 2 | 2026 | 67 | 0.420 |
Why?
|
| Mice, Inbred C57BL | 7 | 2020 | 3485 | 0.390 |
Why?
|
| Biomarkers | 4 | 2024 | 1480 | 0.390 |
Why?
|
| Cell Migration Inhibition | 1 | 2012 | 7 | 0.380 |
Why?
|
| Ligands | 4 | 2023 | 415 | 0.380 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2012 | 64 | 0.370 |
Why?
|
| Skin Neoplasms | 3 | 2014 | 408 | 0.370 |
Why?
|
| ADAM Proteins | 1 | 2012 | 36 | 0.370 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2011 | 49 | 0.360 |
Why?
|
| Keratinocytes | 3 | 2023 | 72 | 0.360 |
Why?
|
| Sezary Syndrome | 2 | 2011 | 2 | 0.350 |
Why?
|
| Bleomycin | 2 | 2023 | 35 | 0.350 |
Why?
|
| Cytokines | 6 | 2024 | 952 | 0.350 |
Why?
|
| Dipeptidyl Peptidase 4 | 1 | 2010 | 6 | 0.330 |
Why?
|
| Dogs | 4 | 2026 | 315 | 0.310 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2012 | 604 | 0.300 |
Why?
|
| Flow Cytometry | 4 | 2018 | 663 | 0.300 |
Why?
|
| Interferon-gamma | 5 | 2018 | 574 | 0.300 |
Why?
|
| Immunity, Innate | 1 | 2013 | 827 | 0.260 |
Why?
|
| Dermatitis, Atopic | 1 | 2026 | 29 | 0.240 |
Why?
|
| Simvastatin | 2 | 2017 | 26 | 0.230 |
Why?
|
| Immunity, Cellular | 2 | 2019 | 170 | 0.230 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2026 | 247 | 0.220 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2026 | 183 | 0.210 |
Why?
|
| Genetic Therapy | 1 | 2011 | 839 | 0.200 |
Why?
|
| Female | 14 | 2026 | 34018 | 0.200 |
Why?
|
| Neoplasms | 1 | 2014 | 1368 | 0.200 |
Why?
|
| Proteomics | 1 | 2024 | 293 | 0.180 |
Why?
|
| Interferon Regulatory Factors | 1 | 2022 | 43 | 0.180 |
Why?
|
| Th2 Cells | 1 | 2022 | 93 | 0.180 |
Why?
|
| Connective Tissue Diseases | 1 | 2022 | 11 | 0.180 |
Why?
|
| Mice, Transgenic | 4 | 2018 | 1290 | 0.180 |
Why?
|
| Up-Regulation | 1 | 2023 | 374 | 0.180 |
Why?
|
| Multiple Sclerosis | 1 | 2024 | 226 | 0.180 |
Why?
|
| Scleroderma, Systemic | 1 | 2021 | 20 | 0.170 |
Why?
|
| Severity of Illness Index | 3 | 2017 | 1559 | 0.160 |
Why?
|
| Biological Products | 1 | 2022 | 93 | 0.160 |
Why?
|
| Fibroblasts | 1 | 2023 | 422 | 0.160 |
Why?
|
| Cross-Priming | 1 | 2020 | 15 | 0.160 |
Why?
|
| Melanoma, Experimental | 1 | 2020 | 42 | 0.160 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2012 | 450 | 0.160 |
Why?
|
| Autoantigens | 1 | 2021 | 139 | 0.160 |
Why?
|
| Cells, Cultured | 3 | 2014 | 2188 | 0.160 |
Why?
|
| Cell Movement | 2 | 2019 | 482 | 0.150 |
Why?
|
| Antirheumatic Agents | 1 | 2022 | 227 | 0.150 |
Why?
|
| Phenotype | 2 | 2024 | 1233 | 0.150 |
Why?
|
| Receptors, Interleukin-15 | 1 | 2018 | 2 | 0.140 |
Why?
|
| Interferon Type I | 1 | 2020 | 196 | 0.140 |
Why?
|
| Molecular Targeted Therapy | 1 | 2019 | 128 | 0.140 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2017 | 214 | 0.130 |
Why?
|
| Gene Expression | 1 | 2020 | 852 | 0.130 |
Why?
|
| Male | 11 | 2024 | 31047 | 0.130 |
Why?
|
| Blister | 1 | 2017 | 15 | 0.130 |
Why?
|
| Antigens, CD | 1 | 2018 | 342 | 0.130 |
Why?
|
| Lymphocyte Count | 1 | 2017 | 71 | 0.130 |
Why?
|
| Skin Physiological Phenomena | 1 | 2014 | 16 | 0.110 |
Why?
|
| Skin Pigmentation | 1 | 2014 | 33 | 0.110 |
Why?
|
| Mycosis Fungoides | 1 | 2014 | 3 | 0.110 |
Why?
|
| Receptors, CCR4 | 1 | 2014 | 4 | 0.110 |
Why?
|
| Subcutaneous Fat | 1 | 2014 | 50 | 0.100 |
Why?
|
| Genetic Vectors | 1 | 2020 | 918 | 0.100 |
Why?
|
| Immunity | 1 | 2014 | 107 | 0.100 |
Why?
|
| Wound Healing | 1 | 2014 | 193 | 0.100 |
Why?
|
| Middle Aged | 8 | 2024 | 18273 | 0.100 |
Why?
|
| Lymphocyte Activation | 2 | 2012 | 753 | 0.100 |
Why?
|
| Autoimmunity | 2 | 2026 | 247 | 0.090 |
Why?
|
| Adaptive Immunity | 1 | 2013 | 105 | 0.090 |
Why?
|
| ADAM17 Protein | 1 | 2012 | 8 | 0.090 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 2012 | 62 | 0.090 |
Why?
|
| Gene Expression Profiling | 2 | 2026 | 794 | 0.090 |
Why?
|
| Prognosis | 2 | 2021 | 1784 | 0.090 |
Why?
|
| Bone Marrow Cells | 1 | 2012 | 237 | 0.090 |
Why?
|
| Lymphoma, T-Cell, Cutaneous | 1 | 2011 | 10 | 0.090 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2012 | 211 | 0.090 |
Why?
|
| Enzyme Activation | 1 | 2012 | 391 | 0.090 |
Why?
|
| Genome-Wide Association Study | 1 | 2013 | 361 | 0.090 |
Why?
|
| Lymph Nodes | 1 | 2012 | 233 | 0.090 |
Why?
|
| Stress, Physiological | 1 | 2013 | 210 | 0.090 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2011 | 115 | 0.090 |
Why?
|
| Lentivirus | 1 | 2011 | 64 | 0.080 |
Why?
|
| Mice, SCID | 1 | 2011 | 518 | 0.080 |
Why?
|
| Neoplasm Proteins | 1 | 2011 | 285 | 0.080 |
Why?
|
| Cell Cycle | 1 | 2011 | 398 | 0.080 |
Why?
|
| Neoplasm Staging | 1 | 2010 | 544 | 0.070 |
Why?
|
| Adult | 6 | 2024 | 17358 | 0.070 |
Why?
|
| Cell Differentiation | 1 | 2012 | 1386 | 0.060 |
Why?
|
| Cell Line, Tumor | 1 | 2011 | 1565 | 0.060 |
Why?
|
| Doxorubicin | 1 | 2026 | 98 | 0.060 |
Why?
|
| Young Adult | 3 | 2023 | 4809 | 0.050 |
Why?
|
| Adolescent | 3 | 2023 | 6297 | 0.050 |
Why?
|
| Gene Expression Regulation | 2 | 2026 | 1630 | 0.050 |
Why?
|
| Janus Kinase 1 | 1 | 2023 | 17 | 0.050 |
Why?
|
| Acrylamides | 1 | 2023 | 13 | 0.050 |
Why?
|
| Aminopyridines | 1 | 2023 | 34 | 0.050 |
Why?
|
| RNA, Double-Stranded | 1 | 2023 | 112 | 0.050 |
Why?
|
| Skin Transplantation | 1 | 2023 | 154 | 0.050 |
Why?
|
| Biomarkers, Tumor | 1 | 2026 | 524 | 0.050 |
Why?
|
| Aged | 3 | 2020 | 14965 | 0.050 |
Why?
|
| Janus Kinases | 1 | 2022 | 16 | 0.050 |
Why?
|
| STAT Transcription Factors | 1 | 2022 | 17 | 0.050 |
Why?
|
| Child | 2 | 2022 | 4607 | 0.040 |
Why?
|
| Tissue Distribution | 1 | 2022 | 293 | 0.040 |
Why?
|
| gp100 Melanoma Antigen | 1 | 2020 | 6 | 0.040 |
Why?
|
| Hyaluronan Receptors | 1 | 2020 | 35 | 0.040 |
Why?
|
| Mice, Knockout | 1 | 2026 | 2157 | 0.040 |
Why?
|
| Receptor, Interferon alpha-beta | 1 | 2020 | 53 | 0.040 |
Why?
|
| Vaccinia virus | 1 | 2020 | 69 | 0.040 |
Why?
|
| B7-H1 Antigen | 1 | 2020 | 60 | 0.040 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2020 | 64 | 0.040 |
Why?
|
| Cell Proliferation | 2 | 2014 | 1038 | 0.040 |
Why?
|
| Piperidines | 1 | 2020 | 73 | 0.040 |
Why?
|
| Treatment Outcome | 2 | 2023 | 5792 | 0.040 |
Why?
|
| Pyrimidines | 1 | 2020 | 145 | 0.040 |
Why?
|
| Immune System | 1 | 2020 | 132 | 0.040 |
Why?
|
| Stem Cell Factor | 1 | 2018 | 27 | 0.040 |
Why?
|
| Biopsy | 1 | 2020 | 456 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2023 | 2483 | 0.030 |
Why?
|
| Chemokine CXCL11 | 1 | 2017 | 4 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2024 | 2701 | 0.030 |
Why?
|
| Suction | 1 | 2017 | 33 | 0.030 |
Why?
|
| Body Surface Area | 1 | 2017 | 10 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2023 | 981 | 0.030 |
Why?
|
| Disease Progression | 1 | 2021 | 1220 | 0.030 |
Why?
|
| ROC Curve | 1 | 2017 | 292 | 0.030 |
Why?
|
| Aged, 80 and over | 2 | 2020 | 5614 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2017 | 371 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2024 | 2244 | 0.030 |
Why?
|
| Pigmentation | 1 | 2014 | 25 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2017 | 739 | 0.030 |
Why?
|
| STAT1 Transcription Factor | 1 | 2014 | 35 | 0.030 |
Why?
|
| Chemokine CCL22 | 1 | 2014 | 1 | 0.030 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2014 | 16 | 0.030 |
Why?
|
| Receptors, Cytokine | 1 | 2014 | 13 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2017 | 1141 | 0.030 |
Why?
|
| Chemokines, CXC | 1 | 2012 | 33 | 0.020 |
Why?
|
| Microscopy, Fluorescence | 1 | 2014 | 401 | 0.020 |
Why?
|
| Lymphocytic Choriomeningitis | 1 | 2012 | 52 | 0.020 |
Why?
|
| S-Phase Kinase-Associated Proteins | 1 | 2011 | 7 | 0.020 |
Why?
|
| HSC70 Heat-Shock Proteins | 1 | 2011 | 9 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2011 | 32 | 0.020 |
Why?
|
| Sequence Analysis, Protein | 1 | 2011 | 31 | 0.020 |
Why?
|
| DNA, Neoplasm | 1 | 2011 | 61 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2011 | 58 | 0.020 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2011 | 364 | 0.020 |
Why?
|
| Sequence Alignment | 1 | 2011 | 300 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2011 | 414 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2011 | 676 | 0.020 |
Why?
|
| Dendritic Cells | 1 | 2012 | 531 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2011 | 1589 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2011 | 1979 | 0.020 |
Why?
|
| Protein Binding | 1 | 2012 | 1640 | 0.020 |
Why?
|
| DNA-Binding Proteins | 1 | 2012 | 1225 | 0.010 |
Why?
|
| Mutation | 1 | 2011 | 2661 | 0.010 |
Why?
|